Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer.
Intetumumab (CNTO 95; 0-5 μg/mL; 20 min; USPC-ARK-3 cells) inhibits integrin-mediated USPC cell adherence to a vitronectin substratum and inhibits serum-induced migration of USPC cells[1].
Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung[2].
References:
[1]. Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90.
[2]. Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.